NDAORALTABLET
Approved
Jun 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
TENORETIC 50 (atenolol and chlorthalidone) by Lavipharm is adrenergic beta-antagonists [moa]. Approved for hypertension, to lower blood pressure, heart failure. First approved in 1984.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TENORETIC 50 is a fixed-dose combination tablet containing atenolol (beta-blocker) and chlorthalidone (thiazide diuretic) approved in 1984 for hypertension and heart failure. It reduces blood pressure through dual mechanisms: beta-adrenergic blockade of cardiac output and diuretic-induced sodium/fluid depletion. The combination addresses both static and dynamic components of hypertension pathophysiology.
$0.107MPart D
LOE ApproachingDeclining
Minimal commercial growth expected; product approaching loss of exclusivity signals consolidation of brand team and shift toward generic transition management.
Mechanism of Action
Adrenergic beta-Antagonists
Pharmacologic Class:
beta-Adrenergic Blocker
Indications (3)
Worked on TENORETIC 50 at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.